Intercept Pharma

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Intercept Pharma reports robust earnings, eyes growth amid competitive challenges

Intercept Pharma's Q4 2022 earnings call highlighted strong financial performance, strategic advancements, and a focus on innovation and market expansion.
The company's achievements in sales growth, patent protection, and financial stability position it well for future growth and leadership in the PBC and NASH markets.
Challenges in competitive dynamics and regulatory landscape require proactive strategies, while opportunities in new programs and market developments offer avenues for continued success.
Overall, Intercept Pharma's performance underscores a resilient and forward-thinking approach to navigating the complexities of the pharmaceutical industry and driving sustainable growth.

Intercept Pharma reports growth in sales and navigates NASH landscape

Intercept Pharma's Q1 2023 performance saw growth in net sales and strong sales performance of OCALIVA.
The company's focus on F3-like NASH patients and competitive positioning of OCA are key strengths.
Challenges include pricing strategy discussions and questions on combination approaches.
Opportunities lie in addressing AdCom discussions, expanding prescriber base, and preventing cirrhosis progression.

Intercept Pharma reports strong Q2 earnings, eyes FDA relations

Intercept Pharma's strong performance in Q2 2023 shows progress towards profitability by 2024. The company is addressing challenges in FDA relations and study enrollments while leveraging market opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)-- #InterceptPharmaceuticals--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Intercepts Pharmaceuticals, Inc. (NASDAQ: ICPT) on behalf of Intercept stockholders. Our investigation concerns whether Intercept has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On October 8, 2020, news outlets reported that Intercept was “facing an investi

INTERCEPT PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. is Investigating Intercept Pharmaceuticals, Inc. on Behalf of Intercept Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2020 financial results prior to market open on Monday, November 9, 2020. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.

Intercept to Announce Third Quarter 2020 Financial Results on November 9, 2020

Atlanta, Georgia--(Newsfile Corp. - November 2, 2020) - Holzer & Holzer, LLC is investigating whether Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) ("Intercept" or the "Company") complied with federal securities laws. In its most recent 10-Q filed with the SEC, the Company disclosed "the FDA has notified us that in the course of its routine safety surveillance, in May 2020 the FDA began to evaluate a newly identified safety signal regarding liver disorder for Ocaliva...

SHAREHOLDER ALERT: Investigation of Intercept Announced by Holzer & Holzer, LLC

Los Angeles, California--(Newsfile Corp. - October 30, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ: ICPT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. News outlets reported on October 8, 2020, that Intercept is "facing...

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK, Oct. 29, 2020 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, is investigating whether Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT), or certain of its officers...

Scott+Scott Attorneys at Law LLP Announces Investigation into Intercept Pharmaceuticals, Inc. (ICPT)

LOS ANGELES--(BUSINESS WIRE)---- $ICPT #classaction--The Law Offices of Frank R. Cruz announces an investigation of Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDQ: ICPT) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On October 8, 2020, it was reported that the Company is “facing an investigation from the U.S. Food and Drug Administration over the potential risk of liver inj

The Law Offices of Frank R. Cruz Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $ICPT #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors

Presentation of l ong -term efficacy and safety data of obeticholic acid (OCA ) for the treatment of patients with PBC

New PBC and NASH Data to be Presented at AASLD's The Liver Meeting Digital Experience™

LOS ANGELES--(BUSINESS WIRE)---- $ICPT #CLASSACTION--Glancy Prongay & Murray, Leading Securities Fraud Law Firm, Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $ICPT #ICPT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) resulting from allegations that Intercept may have issued materially misleading business information to the investing public. On October 8, 2020, news outlets reported that Intercept was “facing an investigation from the U.S. Food and Drug Administration over the potential risk of liver

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Intercept Pharmaceuticals, Inc. – ICPT

The company's share price is down more than 60% for the year, but could positive news on its new nonalcoholic steatohepatitis (NASH) drug make an investor a millionaire?

Could Intercept Pharmaceuticals Be a Millionaire-Maker Stock?

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

Intercept (ICPT) Down 16.2% Since Last Earnings Report: Can It Rebound?

Intercept (ICPT) plans to lay off its workforce to save costs and streamline operations.

Intercept's (ICPT) Stock Rises After Layoff Announcement

NEW YORK, Sept.  03, 2020  (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President and Chief Executive Officer and Sandip Kapadia, Chief Financial Officer of Intercept, will present at the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020 at 12:00 p.m. ET.

Intercept to Present at September Investor Conference

Shares of Intercept Pharmaceuticals Inc.  were up 2.2% in premarket trading on Wednesday, the day after the company told investors that it planned to lay off 170 employees, which is one-quarter of its workforce, by the end of the year.

Intercept shares gain after it announces layoffs

Intercept (ICPT) releases new favorable outcome on OCA from the REGENERATE study, which evaluated patients with liver fibrosis due to NASH.

Intercept (ICPT) Posts New Positive Results on NASH Drug

NEW YORK, Aug.  27, 2020  (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional data indicating that obeticholic acid (OCA) helped patients with nonalcoholic steatohepatitis (NASH) achieve sustained improvements in liver biochemistry and noninvasive markers of liver fibrosis over two years of treatment. The new results based upon a post hoc review of the interim analysis data from the Phase 3 REGENERATE study are being presented at the virtual International Liver Congress™ 2020, the 55th Annual Meeting of the European Association for the Study of the Liver (EASL).

New Data from the Interim Analysis of REGENERATE Show that OCA Helped Patients with Liver Fibrosis Due to NASH Achieve Sustained Improvement in Noninvasive Markers of Fibrosis Over Two Years of Treatment

New analyses of the interim analysis data from the Phase 3 REGENERATE study describe the benefit of obeticholic acid (OCA) on noninvasive measures of liver fibrosis in NASH patients on treatment for at least 24 months

Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2020

A better-than-expected quarter helps ease the pain of a recent FDA denial.

Intercept Pharmaceuticals Notches Convincing Q2 Beats

Intercept (ICPT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Intercept (ICPT) Catches Eye: Stock Jumps 8.4%

Intercept (ICPT) reports better-than-expected results for the second quarter of 2020.

Intercept's (ICPT) Q2 Earnings and Revenues Beat Estimates

Intercept Pharmaceuticals (ICPT) Q2 2020 Results - Earnings Call Transcript

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) rose 2% in pre-market trading after the company reported Q2 results.

Recap: Intercept Pharmaceuticals Q2 Earnings

Worldwide Ocaliva net sales of $77.2 million in the second quarter 2020, representing 17% growth over the prior year quarter 

News for Intercept Pharma Stock (ICPT)